<DOC>
	<DOCNO>NCT00024518</DOCNO>
	<brief_summary>This study see interferon-alpha give early disease stop slow immune attack insulin-producing cell . In addition , study examine safety efficacy interferon-alpha ( give mouth ) protect beta cell function . Patients 3 25 year age Type 1 Diabetes Mellitus le six week may eligible study . All study-related test medication NIH Clinical Center provide cost .</brief_summary>
	<brief_title>Interferon-Alpha Diabetes Mellitus Type 1</brief_title>
	<detailed_description>Type 1 diabetes mellitus ( T1DM ) result autoimmune destruction insulin-producing pancreatic beta-cells . The onset clinical symptom represent endpoint chronic progressive decline beta-cell function number functional beta-cells descend critical mass require maintenance euglycemia ( [ 1 ] , [ 2 ] ) . However , pancreas still retain ability produce substantial amount insulin . The goal secondary prevention T1DM avert destruction remain beta-cells therefore delay stop entry final stage disease associate end organ damage . The rationale study interfere autoimmune beta-cell destruction early order preserve much residual endogenous insulin production possible . We plan administer oral interferon-alpha ( IFN-a ) daily basis , show modify clinical course diabetes , alter cytokine release , reduce expression T cell activation marker animal model ( [ 3 ] ) pilot project human ( S. Brod , University Texas , unpublished data ) . The one-year study design double blind randomize protocol use either 5,000 30,000 unit IFN-a versus placebo . Five center participate protocol ( University Texas Health Science Center Houston ; Dallas ; Children 's Hospital , St. Paul , MN ; Kansas City NIH , Bethesda , Maryland ) .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>INCLUSION CRITERIA : T1DM le 6 week duration patient 3 25 year age . Besides T1DM , concurrent illness . EXCLUSION CRITERIA : Treatment immunosuppressive immunostimulatory medication azathioprine , nicotinamide , superoxide dismutasedesferroxamine , aminoguanidine , oral insulin experimental therapy present time past . Abnormal pretreatment white blood cell count ( WBC ) thrombocytopenia . Known active disease , e.g . cardiac , renal , hepatic disease immunodeficiency . History cancer , neuropathy seizure disorder ( except typical history febrile seizure childhood ) , peripheral vascular disease , coagulation abnormality , autoimmune disease ( except type 1 diabetes ) cerebrovascular disease . Ongoing use medication know influence glucose tolerance ( e.g . sulfonylurea , metformin , diphenylhydantoin , thiazide potassium deplete diuretic , betaadrenergic blocker , niacin ) except insulin . Any medical condition , opinion investigator , interfere safe completion trial . Inability give inform consent assent . Participation clinical trial within previous 6 week . Lactating pregnant female individual ( individual advise volunteer protocol plan become pregnant time study instruct use effective method contraception ) . Age 25 year , since may several subtypes T1DM .</criteria>
	<gender>All</gender>
	<minimum_age>3 Years</minimum_age>
	<maximum_age>25 Years</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>Diabetes</keyword>
	<keyword>Immunotherapy</keyword>
	<keyword>Study Drug</keyword>
	<keyword>Insulin Dependent Diabetes</keyword>
	<keyword>Diabetes Mellitus</keyword>
	<keyword>TIBM</keyword>
</DOC>